Get the Stockscreener App
355.20
0.32%
1.14
Pre-market:
355.40
0.20
+0.06%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $355.20, with a volume of 2.73M.
It is up +0.32% in the last 24 hours and up +5.62% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$354.06
Open:
$357.395
24h Volume:
2.73M
Relative Volume:
1.04
Market Cap:
$191.70B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
24.70
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+1.61%
1M Performance:
+5.62%
6M Performance:
+11.79%
1Y Performance:
+19.48%
1-Day Range:
$351.96
$358.17
1-Week Range:
$337.49
$358.46
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
355.20 | 191.70B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,133.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.87 | 579.83B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.73 | 402.35B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 294.03B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.07 | 292.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PR Newswire
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN - MarketBeat
Atlas Capital Advisors Inc. Takes $2.20 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st
Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna - Insider Monkey
Wall Street Zen Upgrades Amgen (NASDAQ:AMGN) to Buy - MarketBeat
Amgen Inc. Stock (US0311621009): Biotech heavyweight in focus as investors weigh valuation and pipel - AD HOC NEWS
Victory Capital Management Inc. Grows Holdings in Amgen Inc. $AMGN - MarketBeat
State Street Corp Has $10.01 Billion Stock Position in Amgen Inc. $AMGN - MarketBeat
Van ECK Associates Corp Lowers Position in Amgen Inc. $AMGN - MarketBeat
Is Amgen Still Reasonable After Its Strong Run? - Kalkine Media
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now - Insider Monkey
Korea Investment CORP Trims Stake in Amgen Inc. $AMGN - MarketBeat
Operating expenses (excl. COGS) of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Rhenman & Partners Asset Management AB Acquires Shares of 36,000 Amgen Inc. $AMGN - MarketBeat
First National Bank of Omaha Boosts Position in Amgen Inc. $AMGN - MarketBeat
Amgen taps research firm to reassess Tavneos data - Reuters
Amgen (AMGN) Stock After Horizon Deal And Strong Multi‑Year Gains Is Price Still Reasonable - simplywall.st
Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial - Law360
Amgen owes $20.2 million in antibody patent lawsuit, US jury says - marketscreener.com
Amgen Turns to an Independent Review to Defend Rare Disease Drug in FDA Crosshairs - MedCity News
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says - TradingView
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Benzinga
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Benzinga
Amgen’s ABP 938 Takes Aim at EYLEA HD in High-Stakes Eye Disease Trial - TipRanks
Amgen Defends Tavneos Amid FDA Withdrawal Proposal - GuruFocus
Cash from investing activities of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug - Investing.com
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug By Investing.com - Investing.com Canada
Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight - GuruFocus
(AMGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $427 - Moomoo
Amgen Inc. $AMGN Position Reduced by Vaughan David Investments LLC IL - MarketBeat
Swiss National Bank Has $482.87 Million Holdings in Amgen Inc. $AMGN - MarketBeat
ICICI Prudential Asset Management Co Ltd Has $8.87 Million Stake in Amgen Inc. $AMGN - MarketBeat
9,812 Shares in Amgen Inc. $AMGN Bought by Meiji Yasuda America Inc - MarketBeat
Nuveen LLC Sells 86,287 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Stock (US0311621009): Shares Jump On EU Cancer Drug Approval And New Trial Data - AD HOC NEWS
Amgen Inc. Stock (US0311621009): Dow component under pressure after recent pullback - AD HOC NEWS
Aviva PLC Purchases 23,465 Shares of Amgen Inc. $AMGN - MarketBeat
A Look at Amgen Inc (AMGN) After 4.8% Gain -- GF Value $353.35 vs Price $354.06 - GuruFocus
Amgen (AMGN) Faces FDA Scrutiny Over Tavneos Amid Safety Concerns - GuruFocus
Amgen Reevaluates Tavneos Data as Drug Faces FDA Scrutiny - Bloomberg.com
A Look at Amgen Inc (AMGN) After 4.8% Gain -- GF Value $353.35 v - GuruFocus
Amgen hires Duke research organization to save Tavneos from market removal - Seeking Alpha
Amgen taps Duke Research Institute to reevaluate disputed Tavneos data - Investing.com
Amgen taps Duke Research Institute to reevaluate disputed Tavneos data By Investing.com - Investing.com Canada
Amgen’s Repatha Diabetes Data Reframes Cardiometabolic Upside For Investors - simplywall.st
Amgen Reevaluates Tavneos Data as Medicine Faces FDA Scrutiny - Bloomberg.com
Amgen Hires Avenue Solutions for Medicare Lobbying - Legis1
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):